<SEC-DOCUMENT>0001171843-22-002448.txt : 20220407
<SEC-HEADER>0001171843-22-002448.hdr.sgml : 20220407
<ACCEPTANCE-DATETIME>20220407161015
ACCESSION NUMBER:		0001171843-22-002448
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20220407
FILED AS OF DATE:		20220407
DATE AS OF CHANGE:		20220407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Genfit S.A.
		CENTRAL INDEX KEY:			0001757064
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38844
		FILM NUMBER:		22813963

	BUSINESS ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
		BUSINESS PHONE:		33 3 20 16 4000

	MAIL ADDRESS:	
		STREET 1:		PARC EURASANTE
		STREET 2:		885, AVENUE EUGENE AVINEE
		CITY:			LOOS
		STATE:			I0
		ZIP:			59120
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_040722.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of report: Thursday April 7, 2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-38844 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENFIT S.A. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&#8217;s name into
English) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Parc Eurasant&eacute;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>885, avenue Eug&egrave;ne Avin&eacute;e</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>59120 Loos, France</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%; text-align: left">&#9746; Form 20-F</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 79%; text-align: left">&#9744; Form 40-F</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT LIST </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Exhibit</B></P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Description</B></P></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="exh_991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated
    April 7, 2022.</FONT></A></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 48%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT S.A.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">Date: Thursday April 7, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Pascal PRIGENT</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #005478"><FONT STYLE="font-size: 14pt"><B>GENFIT
Reports Full-Year 2021 Financial Results and Provides Corporate Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.85pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cash and cash equivalents totaled &#8364;258.8
million as of December 31, 2021</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: left"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Major financial achievements
in 2021 include landmark strategic partnership deal with Ipsen, successful convertible debt renegotiation and non-dilutive funding through
French State-Guaranteed Loans</B></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: left"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Important R&amp;D milestones
reached in 2021, including launch of Phase 1 in acute on chronic liver failure (ACLF), in-licensing of GNS561 (a novel molecule) in cholangiocarcinoma
(CCA) and recognition of NIS4&reg; technology&#8217;s unique performance by FNIH NIMBLE study</B></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: left"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outlook 2022</B></FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 64.9pt"></TD><TD STYLE="width: 18pt">o</TD><TD STYLE="padding-right: 10.7pt"><B>Elafibranor in Primary Biliary Cholangitis (PBC): commitment for topline data readout in the second
quarter 2023 reaffirmed</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 64.85pt"></TD><TD STYLE="width: 18.05pt">o</TD><TD><B>NTZ in ACLF: Phase 1 data expected by third quarter 2022</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 64.85pt"></TD><TD STYLE="width: 18.05pt">o</TD><TD><B>GNS561 in CCA: target to start Phase 1b/2 trial by fourth quarter 2022</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.85pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Conference call (English and French) on April
8, 2022 at 8am ET / 1pm GMT / 2pm CET</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #005278"><B>Lille,
France; Cambridge, MA; April 7, 2022 </B></FONT>- <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GENFIT (Nasdaq and Euronext:
GNFT)</B></FONT>, a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases,
today announced annual financial results for the year ended December 31, 2021. A summary of the consolidated financial statements is included
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.6pt 0pt 10.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #005478"><B>Pascal
Prigent, CEO of GENFIT</B></FONT>, commented: <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&#8220;2021 was a pivotal year
for us. We are pleased to have delivered on our key commitments which were to improve our financial situation, pursue our Phase 3 trial
and strengthen our pipeline. We are grateful to our dedicated team for their efforts in realizing these objectives and our investors for
their continued support. We start 2022 having made great progress regarding ELATIVE&#8482;, and our improved financial visibility will
enable us to grow our pipeline and</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 10.9pt; text-align: justify"><I>accelerate our existing programs,
as we continue to seek therapeutic and diagnostic solutions that can improve the health and quality of life of patients affected by severe
chronic liver diseases.&#8221;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #005478"><FONT STYLE="font-size: 12pt">Financial
results*</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt;">
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-top: Black 1pt solid; text-align: left">KEY FIGURES (CONSOLIDATED)</TD><TD STYLE="border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">(in &euro; thousands, except earnings per share data)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap">31/12/2020</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap">31/12/2021</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #DAEDF3">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Revenues and other income</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">7 758</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">85 579</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(59 097</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(35 166</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(14 270</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(16 153</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Marketing and market access expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(11 216</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1 539</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 70%; text-align: left">Reorganization and restructuring expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">(5 308</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(142</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Other operating income (expenses)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(764</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(763</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #DAEDF3">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Operating income (loss)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(82 897</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">31 816</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Financial income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6 544</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">44 780</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Financial expenses</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(25 296</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(7 122</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #DAEDF3">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Financial profit (loss)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(18 752</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">37 658</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Net profit (loss) before tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(101 649</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">69 474</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Income tax benefit (expense)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">428</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2 215</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #DAEDF3">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Net profit (loss)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(101 221</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">67 259</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Basic earnings (loss) per share (&euro;/share)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,60</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,51</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Diluted earnings (loss) per share (&euro;/share)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0,00</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,23</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Cash, cash equivalents and current financial assets</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">171 029</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">258 756</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">* Unaudited financial statements. The
audit procedures by the Statutory Auditors are underway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #56879F"><FONT STYLE="font-size: 11pt">Revenue
and other operating income</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.6pt 0pt 10.9pt; text-align: justify">Revenue and other operating income
for 2021 amounted to &#8364;85.6 million compared to &#8364;7.8 million for 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">Revenue for 2021 amounted to
&#8364;80.1 million, mainly from the receipt of the &#8364;120.0 million upfront payment from Ipsen, out of which &#8364;80.0
million is recognized as 2021 revenue, after deduction of &#8364;40.0 million deferred revenue, which will gradually be recognized
as revenue following the completion of the ELATIVE&#8482; double-blind study. Other revenue recognized in 2021 is related to
licensing agreements with Labcorp for the deployment of NIS4&reg; technology in NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 10.9pt; text-align: justify">Revenue for 2020 amounted to &#8364;0.8
million, mainly from the license agreements with Labcorp, as well as one-time sales of goods and services within the scope of the collaboration
and license agreement with Terns Pharmaceuticals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">Other operating income included
mainly the research tax credit (known as <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Cr&eacute;dit
d&#8217;Imp&ocirc;t Recherche </I></FONT>or CIR) granted by the French tax authorities, which amounted to &#8364;5.3 million for
2021 compared</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.7pt 0pt 10.9pt; text-align: justify">with &#8364;7.9 million for 2020,
which was reduced by a &#8364;1.9 million expense following the settlement of a dispute relating to the CIR for 2010, 2011, 2012 and 2014.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F"><FONT STYLE="font-size: 11pt">Operating
expenses and operating result</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">Operating expenses for 2021 amounted to &#8364;53.8 million
compared to &#8364;90.7 million for 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.95pt 0pt 10.9pt; text-align: justify">R&amp;D expenditures,
general and administrative expenses, marketing and market access expenses and other operating expenses decreased in 2021 compared to
the previous year, amounting to &#8364;53.6 million compared to &#8364;85.3 million for 2020. This decrease mainly reflected the
effects of the reorganization and restructuring plan, which was initiated during the fourth quarter 2020 and throughout 2021. The
non-recurring costs associated with the implementation of the reorganization and restructuring plan decreased significantly from
&#8364;5.3 million in 2020 to &#8364;0.1 million in 2021, consisting primarily of fees related to the renegotiation of the
convertible bonds, partially offset by the reversal of certain impairment losses and provisions previously booked in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">In 2021, GENFIT generated a consolidated operating result
of &#8364;31.8 million compared to an operating loss of &#8364;82.9 million in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F"><FONT STYLE="font-size: 11pt">Financial
result</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.6pt 0pt 10.9pt; text-align: justify">2021 resulted in a financial income
of &#8364;37.7 million compared to a financial loss of &#8364;18.8 million in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.75pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.75pt 0pt 10.9pt; text-align: justify">This variation was mainly due
to the &#8364;35.6 million one-time bonus relating to the partial buyback of the convertible bonds (OCEANE) and to the decrease in expenses
related to financial interest from &#8364;11.6 million in 2020 to &#8364;4.8 million in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">The foreign exchange result on
cash and cash equivalents was a net gain of &#8364;6.7 million in 2021, compared to a net loss of &#8364;8.5 million in 2020. This mainly
resulted from the effect of the exchange rate fluctuations on the cash investments held in US dollars, which have been kept in their original
currency since they were invested. In connection with the preceding, &#8364;5.9 million out of the total 2021 foreign exchange result
is qualified as unrealized.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F"><FONT STYLE="font-size: 11pt">Cash
and cash equivalents</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">As of December 31, 2021, the Company&#8217;s cash and cash
equivalents amounted to &#8364;258.8 million compared with &#8364;171.0 million as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">This is mainly the result of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: left"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The &#8364;120.0 million non-refundable initial payment received from Ipsen pursuant to the
license agreement signed in December 2021, further increased by &#8364;24.0 million of collected VAT;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.85pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Ipsen&#8217;s &#8364;28.0 million equity investment in GENFIT&#8217;s share capital received in December 2021;</TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.85pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The reimbursement in October 2021 of the 2020 CIR for &#8364;7.9 million;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: left"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The granting of two State-guaranteed loans and a subsidized loan in June, July and November
2021 for a total amount of &#8364;15.2 million;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: left"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">&#8364;47.5 million (not including transaction expenses) disbursed for the partial buyback
of the OCEANE convertible bonds in January 2021; and</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: left"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cash used in operating activities over the period.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">Note: taking into account the
partial buyback of the OCEANEs and the conversions into shares that have taken place since the renegotiation of the convertible debt,
which gave rise to the creation of 6,941,875 new shares, the residual convertible bond debt amounts to a nominal amount of &#8364;56.9
million as of April 7, 2022, i.e. less than a third of the amount of the initial nominal debt of &#8364;180.0 million. The number of OCEANEs
remaining in circulation is 1,923,662, representing a maximum dilution in the event of conversion of all convertible bonds of 17.52% (in
% of capital held as of April 7, 2022).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #005478">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #005478"><FONT STYLE="font-size: 12pt">2021
Key Highlights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #56879F"><FONT STYLE="font-size: 11pt">Financial
&#8211; key highlights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.3pt"><IMG SRC="arr.jpg" ALT="" STYLE="height: 15px; width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successful
convertible debt renegotiation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">We successfully restructured the
convertible debt at the end of January 2021 with a partial buy- back and extended the maturity to October 2025. At the end of 2021, the
outstanding nominal debt was approximately &#8364;56.9 million, i.e. less than a third of the initial nominal debt of &#8364;180.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.3pt"><IMG SRC="arr.jpg" ALT="" STYLE="height: 15px; width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-dilutive
State-Guaranteed Loans for a total amount of &#8364;15.2 million</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">In 2021, GENFIT secured &#8364;15.2
million non-dilutive loans granted in the context of the COVID-19 pandemic, of which &#8364;13 million are guaranteed up to 90% by the
French state.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.3pt"><IMG SRC="arr.jpg" ALT="" STYLE="height: 15px; width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Long-term
strategic partnership with IPSEN</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">In December 2021, GENFIT entered
into an exclusive, worldwide<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT> licensing agreement
with IPSEN for elafibranor, a Phase 3 asset evaluated in Primary Biliary Cholangitis (PBC). Under the terms of the agreement, GENFIT
received an upfront cash payment of &#8364;120.0 million and is eligible for regulatory, commercial and sales-based milestone payments
of up to &#8364;360.0 million. GENFIT is also eligible to receive tiered double-digit royalties of up to 20%. In addition to global commercialization<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>,
IPSEN will be responsible for all clinical development of elafibranor following completion of the ELATIVE&#8482; double-blind period,
including completion of the long-term open-label extension period of the ELATIVE<FONT STYLE="font-size: 10pt">&#8482;</FONT> trial<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
</FONT>To underscore GENFIT and Ipsen&#8217;s long-term partnership, Ipsen has taken an 8% ownership stake for &#8364;28.0 million. Ipsen
has now become GENFIT&#8217;s largest shareholder.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #56879F">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #56879F"><FONT STYLE="font-size: 11pt">Pipeline
development &#8211; key highlights</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.3pt"><IMG SRC="arr.jpg" ALT="" STYLE="height: 15px; width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Elafibranor
development program in PBC</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">Despite the COVID-19 pandemic,
patient enrolment for the Phase 3 ELATIVE&#8482; clinical trial progressed well throughout 2021, with positive Data Safety Monitoring
Board (DSMB) outcomes. In February 2021, the Company announced the publication, in the <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Journal
of Hepatology</I></FONT>, of the positive results of the Phase 2 clinical trial evaluating elafibranor in patients with PBC and an incomplete
response to ursodeoxycholic acid (UDCA). These results show a clinically significant improvement on the primary and composite biochemical
evaluation criteria which is the primary endpoint of the pivotal trial to support accelerated approval. In addition, the results showed
a positive trend on the improvement of pruritus, while preserving a favorable tolerability profile.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.3pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.3pt"><IMG SRC="arr.jpg" ALT="" STYLE="height: 15px; width: 20px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Significant
progress made in implementing our new pipeline strategy</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">In May 2021, we announced our
new strategic direction in R&amp;D which centers around refocusing our efforts in two new franchises with significant unmet medical needs:
Acute on Chronic Liver Failure (ACLF) and cholestatic diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">In November 2021, we announced
the first patient first visit for the evaluation of NTZ in subjects with hepatic impairment and we are currently initiating a Phase 1
study in renal impairment as part of our ACLF program. ACLF is a severe liver disease with a high unmet need. These Phase 1 studies represent
a key milestone in the Company&#8217;s pipeline development and, upon completion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify"><FONT STYLE="font-size: 8pt"><SUP>1
</SUP>With the exception of China, Hong Kong, Taiwan, and Macau where Terns Pharmaceuticals holds the exclusive license to develop and
commercialize elafibranor.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify"><FONT STYLE="font-size: 8pt"><SUP>2
</SUP>Idem.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.6pt 0pt 10.9pt; text-align: justify">and if positive, will enable GENFIT
to progress towards a proof-of-concept study in patients with acute decompensated cirrhosis and ACLF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">In December 2021, GENFIT strengthened
its cholestatic disease franchise through the in-licensing of exclusive rights from Genoscience Pharma to develop and commercialize the
investigational drug GNS561 in cholangiocarcinoma (CCA) in the United States, Canada and Europe, including the United Kingdom and Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">On the diagnostics side of the
business, in November 2021, a study undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE), an initiative of the
Foundation for the National Institutes of Health&#8217;s Biomarkers Consortium (FNIH) confirmed that NIS4&reg; technology demonstrates
a unique performance in identifying patients with at-risk Non-Alcoholic Steatohepatitis (NASH), and provided evidence that it had the
best results <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT><FONT STYLE="font-size: 10pt">f</FONT>
the five blood-based biomarker panels which were assessed in this study<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
</FONT>for the diagnosis of fibrosis stage&#8805; 2. The FNIH NIMBLE findings will have a strong utility for the whole NASH field and
practitioners, and could potentially pave the way for regulatory qualification for non-invasive tests in NASH. NIS4&reg; technology is
currently powering a test called NASHnext&#8482; commercialized by our partner Labcorp in the U.S. and Canada.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #56879F">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #56879F"><FONT STYLE="font-size: 11pt">Organizational
and governance updates</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.85pt 0pt 10.9pt; text-align: justify">In March 2021, Jean-Fran&ccedil;ois
Tin&eacute; was appointed Member of the Board of Directors, replacing Philippe Moons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">In April 2021, GENFIT appointed Thomas
Baetz as Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 10.9pt; text-align: justify">In 2021, GENFIT added four new
members to its Executive Committee: Pascal Caisey (hired as Chief Commercial Officer and promoted Chief Operating Officer in February
2022), Stefanie Magner (Chief Compliance Officer and VP International Legal Affairs), Philippe Mott&eacute; (Chief Regulatory and Quality
Officer) and Thomas Baetz (Chief Financial Officer).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">In October 2021, the Environmental
Social Governance (ESG) Committee was created following new recommendations of the Middlenext Code. The aim of the committee is to measure
and track GENFIT&#8217;s non-financial performance on an annual basis. Ms. Catherine Larue serves as Chairwoman on the ESG Committee.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify"></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #005478"><FONT STYLE="font-size: 12pt">Outlook
2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #56879F"><FONT STYLE="font-size: 11pt">Building
on our strengths to execute our strategy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.5pt 0pt 10.9pt; text-align: justify">We believe our strengths, listed
below, provide the foundation that will allow us to successfully expand our activities in 2022 and beyond:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 31.5pt; text-align: right"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Experience in bringing early-stage assets into late development stages, with expertise ranging
from research to pre-commercialization, and including clinical development and regulatory affairs;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 31.5pt; text-align: right"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A portfolio rationalized in 2021, focusing on disease areas with high unmet needs and high
market potential;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Choosing partners with a strong commercial track-record; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A robust financial situation with a strong cash position.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F"><FONT STYLE="font-size: 11pt">Continuing
elafibranor development program in PBC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.6pt 0pt 10.9pt; text-align: justify">As previously communicated, we
saw a disruption in our clinical operations at the end of last year due to the COVID pandemic and specifically the rise of the Omicron
strain. However, our recruitment numbers rebounded significantly in the first quarter 2022 as the situation normalized. Screening of patients
will stop next week as end of enrollment is now imminent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.6pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.65pt 0pt 10.9pt; text-align: justify">This means that we remain committed
to deliver topline data readout in the second quarter 2023, in line with our previous guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.65pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F"><FONT STYLE="font-size: 11pt">Pursuing
the execution of existing programs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">Our second objective is to continue
the execution of the following programs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: right"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">NTZ in ACLF: following encouraging pre-clinical results, we are moving forward with the Phase
1 trial in hepatic impairment, aiming for data readout by the third quarter 2022. We are also initiating a Phase 1 study in renal impairment,
with data anticipated in the fourth quarter 2022. If positive, both the hepatic and renal studies will be supportive of the ACLF Investigational
New Drug application and proof-of-concept study.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.85pt"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">GNS561 in CCA: we intend to start a Phase 1b/2 trial by the second half 2022.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 28.85pt; text-align: right"></TD><TD STYLE="width: 18.05pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">NASH Diagnostics: our goal is to further establish NIS4&#8482; technology through scientific
publications and increased use in the field.</TD>
</TR></TABLE>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #56879F"><FONT STYLE="font-size: 11pt">Pipeline
strategy and impact on financial outlook</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 10.9pt; text-align: justify">GENFIT will continue to grow and
diversify its pipeline in 2022 by leveraging its expertise in bringing early-stage assets to late-development stages. To achieve this
goal, we follow a dual-track</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.6pt 0pt 10.9pt; text-align: justify">approach based on repurposing
of molecules approved in other indications and in-licensing of molecules developed by other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 10.9pt; text-align: justify">As we continue our efforts to
identify product candidates with the highest potential, conduct pre- clinical studies and clinical trials and advance the development
of our diagnostic test, we expect that our cash used in operational activities will increase to &#8364;65 million in 2022 (excluding exceptional
items of &#8364;30.0 million payable in 2022 in relation to the upfront payment received from Ipsen in late 2021, i.e. primarily VAT collected
and corporate income tax, as well as potential costs and expenses in future business development activities such as in-licensing).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 174.25pt; text-indent: -156.05pt">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">GENFIT will host a conference
call in English and in French on April 8, 2022 at 8.00am ET / 1:00pm GMT / 2:00pm CET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.75pt 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.75pt 0pt 10.9pt; text-align: justify">Both the English and French conference
calls will be accessible on the investor page of our website, under the events section at <FONT>https://ir.genfit.com/</FONT>
or by calling 800-239-9838 (toll-free U.S and Canada), 0800 358 6377 (toll-free UK) or 0805 101 219 (toll-free France) five minutes prior
to the start time (confirmation code: 9241456). A replay will be available shortly after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 199.3pt 0pt 199.2pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 199.3pt 0pt 199.2pt; text-align: center"></P>

<TABLE CELLPADDING="3" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border: Black 1pt solid; text-align: center; width: 100%"><B>APPENDICES</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 123.6pt; text-align: center">Consolidated Statement of Financial
Position*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt;">
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap">ASSETS</TD><TD STYLE="border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-top: Black 1pt solid; text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">As of</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">(in &euro; thousands)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">31/12/2020</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">31/12/2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">171 029</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">258 756</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Current trade and others receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11 919</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">7 236</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1 765</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2 101</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%">Inventories</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Total - Current assets</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">184 717</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">268 097</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left">Non-current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">174</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11 648</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9 015</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Non-current trade and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Other non-current financial assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1 458</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4 431</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Deferred tax assets</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Total - Non-current assets</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">13 403</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">13 623</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #F9BE8F">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Total - Assets</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>198 119</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>281 720</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">*Unaudited financial statements. The audit procedures by
the Statutory Auditors are underway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt;">
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap"><FONT STYLE="font-size: 10pt">SHAREHOLDERS' EQUITY AND LIABILITIES</FONT></TD><TD STYLE="border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; white-space: nowrap">As of</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">(in &euro; thousands)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap">31/12/2020</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">31/12/2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 70%; text-align: left">Current convertible loans</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1 313</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">415</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Other current loans and borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3 035</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1 773</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Current trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25 564</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">40 988</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Current deferred income and revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14 298</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Current provisions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1 031</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">313</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Other current tax liabilities</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">5 051</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Total - Current liabilities</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">31 067</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">62 837</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left">Non-current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Non-current convertible loans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">169 470</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">47 682</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Other non-current loans and borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">11 873</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">24 365</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Non-current trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">451</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">450</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Non-current deferred income and revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25 821</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Non-current employee benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">922</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">864</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Deferred tax liabilities</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">767</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">602</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Total - Non-current liabilities</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">183 482</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">99 786</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left">Shareholders' equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Share capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9 722</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12 454</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Share premium</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">379 057</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">444 438</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Retained earnings (accumulated deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(303 897</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(405 076</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(92</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Net profit (loss)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(101 221</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">67 259</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Total shareholders' equity - Group share</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(16 430</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">119 097</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Non-controlling interests</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Total - Shareholders' equity</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(16 430</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">119 097</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #F9BE8F">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Total - Shareholders' equity &amp; liabilities</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>198 119</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>281 720</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">*Unaudited financial statements. The audit procedures by
the Statutory Auditors are underway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 123.6pt; text-align: center">Statement of Operations*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; white-space: nowrap">Year ended</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">(in &euro; thousands, except earnings per share data)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">31/12/2020</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">31/12/2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"><B><U>Revenues and other income</U></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 70%">Revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">765</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">80 069</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Other income</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6 993</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">5 510</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Revenues and other income</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">7 758</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">85 579</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"><B><U>Operating expenses and other operating income (expenses)</U></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(59 097</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(35 166</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(14 270</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(16 153</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Marketing and market access expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(11 216</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1 539</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Reorganization and restructuring expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(5 308</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(142</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Other operating income (expenses)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(764</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(763</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt;">
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; width: 70%">Operating income (loss)</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right; width: 12%"><FONT STYLE="font-size: 10pt">(82 897</FONT></TD><TD STYLE="border-top: Black 1pt solid; white-space: nowrap; border-bottom: Black 1pt solid; text-align: left; width: 1%">)</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; text-align: right; width: 12%"><FONT STYLE="font-size: 10pt">31 816</FONT></TD><TD STYLE="border-top: Black 1pt solid; white-space: nowrap; border-bottom: Black 1pt solid; text-align: left; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Financial income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>&nbsp;</B>6 544</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>&nbsp;</B>44 780</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Financial expenses</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(25 296</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(7 122</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Financial profit (loss)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(18 752</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">37 658</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Net profit (loss) before tax</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(101 649</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">69 474</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Income tax benefit (expense)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right">428</TD><TD STYLE="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>&nbsp;</B>(2 215</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #F9BE8F">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Net profit (loss)</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>(101 221</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>67 259</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">*Unaudited financial statements. The audit procedures by
the Statutory Auditors are underway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">&nbsp;</P>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 123.6pt; text-align: center">Statement of Cash Flows*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt;">
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-top: Black 1pt solid; white-space: nowrap">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">Year ended</TD><TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Year ended</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">(in &euro; thousands)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">31/12/2020</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; white-space: nowrap; border-bottom: Black 1pt solid">31/12/2021</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"><B><U>Cash flows from operating activities</U></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Net profit (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(101 221</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">67 259</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: left">Reconciliation of net loss to net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Adjustments for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Depreciation and amortization on tangible and intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3 559</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2 742</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Impairment and provision for litigation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3 015</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1 996</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 70%; text-align: left">+ Expenses related to share-based compensation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1 236</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">470</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">- Gain on disposal of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">80</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">420</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Net finance expenses (revenue)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10 335</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4 663</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Income tax expense (benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(428</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2 215</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Other non-cash items including Research Tax Credit litigation including</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1 818</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(35 538</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;Research Tax Credit litigation and Income incurred by renegotiating the convertible bond debt OCEANE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Operating cash flows before change in working capital</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(85 242</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">40 235</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"><B><U>Change in:</U></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Decrease (increase) in trade receivables and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4 344</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">(Decrease) increase in trade payables and other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(11 447</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">55 335</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #C5D9F0">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">Change in working capital</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(11 129</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">59 680</FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">Income tax paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #F9BE8F">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Net cash flows provided by (used in) in operating activities</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>(96 371</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><B>)</B></TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>99 915</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"><B><U>Cash flows from investment activities</U></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">- Acquisition of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(900</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(537</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Proceeds from disposal of / reimbursement of property, plant and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">- Acquisition of financial instruments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3 148</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt;">
  <TR STYLE="vertical-align: bottom; background-color: #F9BE8F">
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 70%; font-weight: bold; text-align: left">Net cash flows provided by (used in) investment activities</TD><TD STYLE="border-top: Black 1pt solid; width: 1%; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; width: 12%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(966</TD><TD STYLE="border-top: Black 1pt solid; white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">)</TD><TD STYLE="border-top: Black 1pt solid; width: 1%; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-top: Black 1pt solid; width: 12%; border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>(3 377</B></FONT></TD><TD STYLE="border-top: Black 1pt solid; white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"><B><U>Cash flows from financing activities</U></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Proceeds from issue of share capital (net)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27 972</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>+ Proceeds from subscription / exercise of share warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Proceeds from new loans and borrowings net of issue costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15 270</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">- Repayments of loans and borrowings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">207</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(48 436</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">- Payments on lease debts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2 150</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1 887</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">- Financial interests paid (including finance lease)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(7 762</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2 109</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">+ Financial interests received</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1 442</FONT></TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">274</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #F9BE8F">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Net cash flows provided by (used in) financing activities</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>(8 256</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><B>)</B></TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>(8 916</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #F9BE8F">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Increase (decrease) in cash and cash equivalents</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>(105 593</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><B>)</B></TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>87 622</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left"><B><U>Cash and cash equivalents at the beginning of the period</U></B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">276 748</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171 029</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Effects of exchange rate changes on cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(126</TD><TD STYLE="white-space: nowrap; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105</TD><TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #F9BE8F">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Cash and cash equivalents at the end of the period</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>171 029</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 10pt"><B>258 756</B></FONT></TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">*Unaudited financial statements. The
audit procedures by the Statutory Auditors are underway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #005478"><B>ABOUT GENFIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.45pt 0pt 10.9pt; text-align: justify">GENFIT is a late-stage biopharmaceutical
company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs. GENFIT
is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades.
Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today
GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">Its R&amp;D is focused on three
franchises: cholestatic diseases, Acute on Chronic Liver Failure (ACLF) and NASH diagnostics. In its cholestatic diseases franchise,
ELATIVE&#8482;, a Phase 3 global trial evaluating elafibranor<FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT> in patients with Primary
Biliary Cholangitis (PBC) is well underway following a successful Phase 2 clinical trial. Topline data is expected to be announced in
the second quarter 2023. In 2021, GENFIT signed an exclusive licensing agreement with IPSEN to develop, manufacture and commercialize
elafibranor in PBC and other indications. <FONT STYLE="font-size: 10pt"><SUP>4</SUP></FONT> GENFIT is also developing GNS561<FONT STYLE="font-size: 10pt"><SUP>1
</SUP></FONT>in cholangiocarcinoma following the acquisition of exclusive rights in this indication from</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">____________________________</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11.95pt 0pt 10.9pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>3</SUP>&nbsp;
</FONT><FONT STYLE="font-size: 8pt">Elafibranor and GNS561 are investigational compounds that have not been reviewed nor been approved
by a regulatory authority</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 14.15pt 0pt 10.9pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>4</SUP>&nbsp;
With</FONT> <FONT STYLE="font-size: 8pt">the exception of China, Hong Kong, Taiwan, and Macau where Terns Pharmaceuticals holds the exclusive
license to develop and commercialize elafibranor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.7pt 0pt 10.9pt; text-align: justify">Genoscience Pharma in 2021<FONT STYLE="font-size: 10pt"><SUP>5</SUP></FONT>.
In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022. As part
of its diagnostic solutions franchise, the Company entered into an agreement with Labcorp in 2021 to commercialize NASHnext&reg;, powered
by GENFIT&#8217;s proprietary diagnostic technology NIS4&reg; in identifying at-risk NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">GENFIT has facilities in Lille
and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment
B of Euronext&#8217;s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT&#8217;s largest shareholders
and holds 8% of the company&#8217;s share capital. <FONT>www.genfit.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify; color: #005478"><B>GENFIT FORWARD LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.6pt 0pt 10.9pt; text-align: justify">This press release contains certain
forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding timelines for patient enrolment completion and topline data readout for our ELATIVE&#8482; Phase
3 trial, timelines for data readout for our Phase 1 studies in ACLF and the start of the Phase 1b/2 trial in CCA, the commercial uptake
for tests powered by NIS4&#8482; technology, our financial outlook including cash flow and cash burn projections and business activity
expansion projections for 2022 and beyond. The use of certain words, including &#8220;consider&#8221;, &#8220;contemplate&#8221;, &#8220;think&#8221;,
&#8220;aim&#8221;, &#8220;expect&#8221;, &#8220;understand&#8221;, &#8220;should&#8221;, &#8220;aspire&#8221;, &#8220;estimate&#8221;,
&#8220;believe&#8221;, &#8220;wish&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;allow&#8221;, &#8220;seek&#8221;, &#8220;encourage&#8221;
or &#8220;have confidence&#8221; or (as the case may be) the negative forms of such terms or any other variant of such terms or other
terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are
based on reasonable expectations and assumptions of the Company&#8217;s management, these forward-looking statements are subject to numerous
known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or
projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in
research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical
trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, impact of the ongoing COVID-19 pandemic,
exchange rate fluctuations, the granting of the research tax credit by the French tax authorities, extensions of State guaranteed loans
maturity and the Company&#8217;s continued ability to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 10.9pt; text-align: justify">____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 13.95pt 0pt 10.9pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><SUP>5</SUP>&nbsp;
</FONT><FONT STYLE="font-size: 8pt">Agreement includes commercialization and development in the United States, Canada and Europe, including
the United Kingdom and Switzerland</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.4pt 0pt 10.9pt; text-align: justify">raise capital to fund its development,
as well as those risks and uncertainties discussed or identified in the Company&#8217;s public filings with the French <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Autorit&eacute;
des March&eacute;s Financiers </I></FONT>(&#8220;AMF&#8221;), including those listed in Chapter 2 &#8220;Main Risks and Uncertainties&#8221;
of the Company&#8217;s 2020 Universal Registration Document filed with the AMF on 23 April 2021 under n&deg; D.21-0350, which is available
on the Company&#8217;s website (www.genfit.com) and on the website of the AMF (www.amf-france.org), and public filings and reports filed
with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) including the Company&#8217;s 2020 Annual Report on Form 20-F filed
with the SEC on April 23, 2021 and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company.
In addition, even if the Company&#8217;s results, performance, financial condition and liquidity, and the development of the industry
in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future
periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable
law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result
of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; color: #005478"><B>CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GENFIT
</B></FONT>| Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt"><FONT STYLE="font-size: 10pt">Tel: +33 3 2016 4000 |</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif">investors@genfit.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PRESS
RELATIONS</B></FONT> | Media</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.9pt">Stephanie Boyer &#8211; Press relations | Tel: +333 2016
4000 | <FONT>stephanie.boyer@genfit.com</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 90%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; color: #706F61"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GENFIT </B></FONT><FONT STYLE="font-size: 10pt">| 885 Avenue Eug&egrave;ne Avin&eacute;e, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com</FONT></P></TD><TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR></TABLE>
<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $9!'(# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#M+,XL8/\
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M55$>6,C_ %B=!0-(C?3/$(U>6^TIA'%(VY/WG 'TKMM(O-9O[7^S]5MU#_\
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MSI<K[!S1WN:F::S5E_\ "2Z$>!K6G?\ @4G^-6;N^L[&)9;R[@MXV.U7FD"
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MPQ93R6$-OJRN9A !L>7*J<\84 *IQ][!9R<[BM6?$-M:VYB,,821B<A>!M'
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M*>!2D<T4[#N*HYJ=:B!J1&I,2)L<4QZ>&XJ-FJ&BTRO(*J2*3G%7'-0L,Y%
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M/VO2IUEC//E$C(K#TZP:;44@NE,:@_-FG<+,N6_BW5X6R;V5@#R"W!K:EO\
M2/$MILN8TAO@.)!T-0>+$TFRM(;6Q3+D<O7'ABFTJW*^](:\S;CT62PU&!;I
M0\&<[^U;_C'6[.ZL;>VL;=8@  V!7.VFHS31;9221TS4$TT5U<.9&(4<468-
MHH$9Y(/UJ_ITTD9P)#MJ1=*@F*K%< 'KR:EGTNXL;0RA=Z_WAS3#6Q'-J"RW
M)$T9([5.B:7<@8;RV/6L(L'^;+;L\C%6K6TDNY?+M5)?O02DSII?"YCLQ=Z;
M<?:5QEDZD5RLI(F8.FU@>5/6M"UU&]T:Z:(LRR*<%>HK1GELM:3,H6.YQ]Y>
M]*Q5C CB,C*D:,6?HHJ\EQJ>AW"&.62%NN%.*UO#;1Z'JGVBX07 7MUQ5#Q%
MJB:IJSW* (O9:+CN:\OB&+7K58=1 ,ZCB3^*MKX>P6VF:TUW=A)47E=WI7FK
MR[V!48/J*VK&^FM(&(<DD4"-+QO?P:IXDEFB79%T"]JP[>2ZT^=9[=OE_P!G
MI5^VUBT+!+R'<<Y)Q736=CX7UJW\N&Y:VN.P88&?Q-,+%G0/&DNG6CE1AG'S
M,O6H=3\*W/BB7^U;34H9)S_RQ).:R?$&A7>DPJH821=GCYX_"L"UN+NR!>WN
M'4Y_A;^E*[#0[_P]X6U>XU:VLM0MGB1&R90.,5VWBV\TQ+*+3HI&?9A-Y/&:
M\OTKQWKFENLLQE:(?QLG6N@7Q);ZCONF@$JOS(F?N^]4+0ANM+N[,!I(3Y>
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M#O+ (F5RF X<''<'TJZ*WAB9SBI*3L<\\)2B^5Q1PO\ PJ3PO_<O/^__ /\
M6KI=+T&UT?1#I-I+<+; ,$)?+(&ZX./4D_C6/_:]P]_?1S:U'9K#.R(C6ZME
M0?6K^AZA<W=[>1/=K=P1!=DRQ! 2>HKDAF2JR4-=7Y=+]+WZ=CJ>6JC%S22L
MO/K;K:W7N8?_  J3PO\ W+S_ +__ /UJ/^%1^%_[EY_W_P#_ *U;D.OSW-Q<
M10V</[F4QYDN0I8@]AMK2,][]D5Q:1F<G!B\[@#UW8_I73#'>T3<)-_)G//
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MXXI<TN*0BK)$)J,FGFHVH&-+5$QIS&HB:M$,*44"E%42><^(XRWBF[/^Y_Z
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M=,$1[:7;D5)MI,5SLZXC-E%245)9Q=S_ *JW_P"N1_\ 0VJF?F-6[LXBMO\
MKD?_ $-JJ*:Z9') DB7#5H1#I5./'6K<;<5C*-S=,NJ1B@X%5Q(::\OO6:5C
M2]RR'Q4JOD5G";!JPDPQ6\'J8U$62<FFYI@D!IP(-=<7H<4T2**E1 3STIBY
M R:D!P0#S579&A7O[V/3=/>X=@"!P*\2UK4GU74Y'9OW8.2:Z[XAZ^&=K2%\
M*O6N%LH7> S3+B)CR?6HD^AHH]1EQ+<75LJVZ,MNIQGH*KW<4%G9F,J9[I^N
MT9 -:VIRV45BOV><E_\ GFO _*J>FZU#IZ>9Y$<LIZ[P&J"KF1;VYFF2)U=0
M.3D5;U6XMT@2"W3"KUXK4U;7X=2LP([6.*4'ED4"LK3[BQ7S7ND,A'09H$8L
M+!I"0?;&*L7+;8@ :ZO[;X:N[=8FM&AF[.& '\JQ[_09R#-:.LL78#K2N-)F
M$LK9 _2K<-U-;R"5-R$5+I]J/M&;A<;3R#4FLS0O,B1+A1UQ1<K8TXM=MM1C
M$.HPAN,!AUJC)86MO<A[67<I/W36+NVL0 1^-7[9_*0N_..1FF*Y/JM[+-&L
M0^Z/2LAN. #5Q+O]XQ8#!]JMVYLI2/-C//4@XQ2N):E*T^5"W>H?M+&0G-;]
MQH@EMS+IT@D7'(KG)(FB<JZD,#S3&TS2MM3E@Y#9K5BNK+4(O*NEVYZ2"J>C
M:1'?12RR-L1!D UE2;H[@[&^0'IVH!%K4-$GM"71A+%U5A5KP[;P'4!<72YA
M7J#4%OJTB#9G<O0@\BK2E=I8,$W=J!Z%77)8I-1=[9 L7851BN9(7RC$>U6I
MK"1F+(V\'L*JM:S*^7B8 =Z!&I!=NZEY#G%(T5K=DL[[6JE(^R$!1DD<]JJ!
MV3G.:07-<>'KR9-]N5E4=@>:K3"2T0PR*4?T/6G66IW5I(#'(ZK]>*UUO+/4
MXV6[4>;V<<&F@=K'-<]2:M6T5PZ-+ C,J#)-2WNE26[AXV#1D]*WK*]BTW0)
MHA&/,EZD^E)@BA9:Y)'^XG.]&'W345W9VT^9;9@">HK'+'+,".IJ2V9VD4!B
M%[TT@9UVC7PT?1;B(QAFF0J3Z5R+L&E:0Y&6K8;4TA*J1N'?-6K5=%OB([D-
M%NZ,&P*G8=[F!$S[_E)P3VK>BU"*WB2*9"5/6K-UX9@LU,]E=K.G4*.M<Y,T
MCSL) 5(_A-5>X6L=E:V7A75-JRR- [#J!_\ 7JP?"UKHZO=6=ZET@Y501G]*
MX*..1I52('<QXK4@OKS2I3%,2#Z&@5RPOB*ZL[UVCR W!STKT/P_XV34M/\
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MIA![5$T STJ1HPWA.#Q7I'A($>%[,?[_ /Z&U<;);#;TKN?#,>SP[:CTW_\
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MNW]?>+VU/O\ G_D=;17)?\)W_P!2KXG_ /!?_P#94?\ "=_]2KXH_P#!?_\
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MV/V*?_KFW\J^>O#OAZ[\3:DUC9201RK&9,S,0N 0.P/K7T9<PEK.=5!+&-@
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M5=6X,HP23GL:@:U>YG,*$#\: $4[K??WID$J X<4A62U5DE7IP,<U6P6DXH
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M5^RUN+F*Z@6XC/&#SBL:Y?.$P5QU!XJJI(]1SVH%L=@=)T6_0R6<HAE')BK
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M*R=SCFIKK3+2YBWV#X;^Z:Q+:UD9#+@@"ECOWMW.&.13L%^Y!-;SV\A66/\
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M2%A0 TBF#(-/)]Z3(H$*),4IE(%,XI#B@!#*37N_P\&?!6G9_P"FG_HQJ\&
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:JNP]:N.AG-DRBG8XI1TI:U1D-VT4ZBF(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>arr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arr.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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JY#1V*-C%M$V,LB>I]3C"X%%:U(J,FD[HB$G)7:L>HT445!04444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
